



# “Recent Advances In The Management And Treatment Of Diabetes Mellitus”

<sup>1</sup>Priyanka Sawant, <sup>2</sup>Hanzala Khan, <sup>3</sup>Leena Thakare

<sup>1</sup>Assistant Professor, <sup>2</sup>B. Pharmacy Student, <sup>3</sup>Assistant Professor

<sup>1</sup>Department of Pharmacy,

<sup>1</sup>M. S. College of Pharmacy, Devghar, Maharashtra, Mumbai University, Maharashtra, India


**Abstract:** Diabetes mellitus is a chronic metabolic disorder that continues to pose a major global health challenge due to its rising prevalence, long-term complications, and significant economic burden. While traditional therapies such as oral hypoglycemic agents and insulin have long served as the foundation of diabetes management, recent advancements in pharmacological innovation, technology-driven monitoring, and predictive analytics have transformed modern care. Emerging drug classes—including SGLT2 inhibitors, GLP-1 receptor agonists, and next generation insulin analogues—offer improved glycemic control along with cardiovascular and renal protection. Complementary technological innovations such as continuous glucose monitoring systems, insulin pumps, and closed-loop artificial pancreas devices enhance precision, reduce glycemic variability, and promote patient-centred care. Additionally, machine learning-based predictive models support early detection, risk stratification, and personalized treatment planning. Despite these improvements, challenges remain regarding cost, accessibility, long-term safety, and technological literacy. This review highlights recent advances in pharmacological, technological, and analytical strategies, discusses their limitations, and outlines future perspectives in achieving personalized, efficient, and equitable diabetes management.

**Keywords:** Diabetes Mellitus, Type 2 Diabetes, SGLT2 Inhibitors, GLP-1 Receptor Agonists, Insulin Therapy, Continuous Glucose Monitoring, Insulin Pumps, Artificial Pancreas, Machine Learning, Predictive Analytics, Pharmacological Advances, Diabetes Technology, Precision Medicine, Glycemic Control, Non-Pharmacological Interventions.

## INTRODUCTION :

Diabetes mellitus is a chronic metabolic disease marked by sustained hyperglycemia resulting from impaired insulin secretion, insulin action, or both, and its rising global prevalence continues to impose a substantial healthcare and economic burden. Although conventional therapies such as oral hypoglycemic agents and insulin injections remain central to diabetes management, their limitations in long-term glycemic control and patient adherence have accelerated interest in more advanced pharmacological and technological interventions. Recent advancements include newer drug classes such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, both of which offer improved metabolic outcomes and added cardiovascular and renal benefits [1,2]

Parallel innovations in technology, including continuous glucose monitoring systems, insulin pumps, and emerging closed-loop artificial pancreas devices, provide more precise and personalized glucose regulation. Furthermore, the integration of machine learning tools for predicting complications and identifying high-risk individuals represents a significant step toward proactive and individualized care. This review synthesizes these developments, evaluating their therapeutic potential, limitations, and implications for shaping the future of diabetes management [3,4]



### **HISTORY OF DIABETES MELLITUS:**

The history of diabetes mellitus can be traced back to ancient civilizations, with its earliest description appearing in the Ebers Papyrus (1550 B.C.) in Egypt, where excessive urination was noted as a hallmark symptom. Ancient Indian physicians Sushruta and Charaka later described a similar condition known as Madhumita (honey urine), characterized by the attraction of ants to the sweet urine of affected individuals [5,6]. The Greek physician Aretaeus of Cappadocia introduced the term “Diabetes”, meaning “to pass through”, while Thomas Willis, in the 17th century, added the term “Mellitus” after observing the sweet taste of patients’ urine. Major scientific breakthroughs followed in the 19th and 20th centuries, beginning with Paul Langerhans’ discovery of pancreatic islet cells and culminating in the landmark discovery of insulin by Frederick Banting and Charles Best in 1921, which transformed diabetes care. Subsequent developments—including oral antidiabetic drugs, modern insulin formulations, and advanced glucose monitoring systems—have progressively evolved diabetes management, shifting it from a once-fatal illness to a manageable chronic condition [7].

### **TYPES OF DIABETES MELLITUS [8-10]:**

Diabetes Mellitus is broadly classified into three main types:

#### **1. Diabetes Mellitus (T1DM)**

✓ **Definition:**

A chronic autoimmune disorder in which the body’s immune system destroys the insulin-producing  $\beta$ -cells of the pancreas, leading to absolute insulin deficiency.

✓ **Causes:**

Strong genetic predisposition (HLA genes), along with environmental triggers such as viral infections, early-life factors, and autoimmune mechanisms.

✓ **Symptoms:** Sudden onset of weight loss, polyuria (frequent urination), polydipsia (excessive thirst), polyphagia (increased hunger), blurred vision, and fatigue; may progress to diabetic ketoacidosis if untreated.

✓ **Management:** Requires lifelong insulin therapy, blood glucose monitoring, a healthy diet, regular physical activity, and ongoing diabetes education to prevent complications.

## 2. Diabetes Mellitus (T2DM)

- ✓ **Definition:** A chronic metabolic disorder characterized by insulin resistance and/or inadequate insulin secretion, leading to persistent hyperglycemia.
- ✓ **Causes:** Obesity, physical inactivity, genetic predisposition, poor dietary habits, ageing, and metabolic syndrome.
- ✓ **Symptoms:** Often asymptomatic in early stages; later symptoms may include blurred vision, slow-healing wounds, recurrent infections, tingling or numbness in extremities, increased thirst, and frequent urination.
- ✓ **Management:** Lifestyle modifications (diet, exercise, and weight control), oral antidiabetic drugs, non-insulin injectables (e.g., GLP-1 agonists), and insulin therapy when required, along with regular monitoring of blood glucose levels.

## 3. Gestational Diabetes Mellitus (GDM)

- ✓ **Definition:** A form of glucose intolerance first identified during pregnancy that is not clearly pre-existing diabetes.
- ✓ **Causes:** Pregnancy-related hormonal changes causing increased insulin resistance, especially in the second and third trimesters.
- ✓ **Symptoms:** Usually asymptomatic; detected through routine prenatal screening such as an oral glucose tolerance test (OGTT).
- ✓ **Management:** Healthy diet, regular exercise, blood glucose monitoring, and insulin therapy if needed; careful maternal and fetal monitoring throughout pregnancy.

### SYMPTOMS OF DIABETES MELLITUS [11,12]:

- Increased thirst (polydipsia)
- Increased hunger (polyphagia)
- Frequent urination (polyuria)
- Unexplained weight loss
- Fatigue and weakness
- Blurred or dim vision
- Slow-healing wounds or sores
- Frequent infections (skin, urinary, or vaginal)
- Numbness, tingling, or burning sensation in hands or feet (peripheral neuropathy)



**TREATMENT AND MANAGEMENT [13-16] :****☀ Lifestyle Modifications**

- **Diet:** Emphasis on whole grains, vegetables, fruits, lean proteins, and reduced intake of sugars, saturated fats, and refined carbohydrates.
- **Exercise:** Regular physical activity (e.g., 30 minutes of moderate exercise most days) enhances insulin sensitivity and supports glucose control.
- **Weight Management:** Achieving and maintaining a healthy body weight is crucial, particularly for individuals with type 2 diabetes.

**☀ Medications**

- **Oral Hypoglycemics:** Medications such as metformin, sulfonylureas, DPP-4inhibitors, and SGLT2 inhibitors are commonly used for Type 2 diabetes.
- **Insulin Therapy:** Mandatory for Type 1 diabetes and used, when necessary, in Type 2 diabetes and some cases of gestational diabetes.
- **Other Injectable Therapies:** Includes GLP-1 receptor agonists and combination injectable therapies for enhanced glycemic control.

**☀ Monitoring**

- **Blood Glucose Monitoring:** Regular self-monitoring using glucometers or continuous glucose monitoring (CGM) systems helps maintain optimal glucose levels.
- **HbA1c Testing:** Measures average blood glucose levels over the past 2–3 months; essential for long-term management.

**☀ Education and Support**

- **Patient Education:** Understanding disease mechanisms, treatment options, lifestyle changes, and self-care practices is essential.
- **Support Systems:** Guidance from healthcare providers, diabetes educators, nutritionists, and support groups enhances effective disease management.

**COMPLICATIONS:**

Diabetes mellitus, when not properly managed, can lead to a wide range of serious and potentially life-threatening complications affecting multiple organs and systems. Persistent high blood glucose levels significantly increase the risk of cardiovascular diseases, including heart attack, stroke, and hypertension, making heart-related conditions a major cause of mortality among diabetic patients. The kidneys are also vulnerable, as long-term uncontrolled diabetes can damage the filtering units, leading to diabetic nephropathy, which is one of the leading causes of kidney failure worldwide [17]. Similarly, prolonged hyperglycemia can harm the small blood vessels of the eyes, resulting in diabetic retinopathy that may progress to vision loss or blindness if untreated. Damage to peripheral nerves, known as neuropathy, can cause numbness, tingling, or pain—particularly in the hands and feet—and, combined with poor

blood circulation, increases the likelihood of developing foot ulcers that may require amputation in severe cases. These complications highlight the importance of early diagnosis, strict glycemic control, and continuous monitoring to prevent long-term health consequences [18,19].

**PREVENTION STRATEGIES 20-22:**❖ **Healthy Diet**

Consume a balanced diet rich in whole grains, fruits, vegetables, lean proteins, and healthy fats. Limit sugary foods, refined carbohydrates, and saturated fats to maintain optimal blood glucose levels.

❖ **Regular Physical Activity**

Engage in at least 150 minutes of moderate-intensity aerobic exercise per week (e.g., walking, cycling, swimming). Regular exercise improves insulin sensitivity and supports weight management.

❖ **Weight Management**

Achieve and maintain a healthy body weight through proper diet and physical activity. Losing even 5–7% of body weight can significantly reduce the risk of developing type 2 diabetes.

❖ **Quit Smoking**

Smoking increases insulin resistance and the risk of type 2 diabetes. Quitting smoking improves overall metabolic health and reduces diabetes-related complications.

❖ **Regular Monitoring**

Individuals with prediabetes or risk factors should regularly check blood glucose levels. Routine health check-ups can help detect early signs of diabetes.

❖ **Limit Alcohol Intake**

Excessive alcohol can contribute to weight gain and impaired glucose metabolism. Follow moderate consumption guidelines: up to one drink/day for women and two for men.

❖ **Stress Management**

Chronic stress can negatively impact insulin sensitivity and lifestyle habits. Use stress-reduction techniques such as meditation, yoga, or deep breathing exercises.

❖ **Adequate Sleep**

Aim for 7–8 hours of quality sleep every night. Poor sleep patterns are linked to insulin resistance and increased diabetes risk.

❖ **Stay Hydrated**


Drink sufficient water throughout the day to support healthy glucose levels and prevent dehydration.

❖ **Education and Awareness**

Understand diabetes risk factors, especially if you have a family history. Participate in awareness programmes that promote lifestyle modifications for diabetes prevention.

**METHODOLOGY:**

This review was conducted through a systematic and comprehensive literature search to evaluate advanced pharmacological, technological, and predictive approaches in the management of diabetes mellitus. Relevant studies published between 2010 and 2025 were identified using electronic databases such as PubMed, Scopus, and Web of Science, with search terms including “Diabetes Mellitus”, “Type 2 Diabetes”, “Pharmacological Therapy”, “SGLT2 Inhibitors”, “GLP-1 Agonists”, “Insulin Delivery Systems”, “Continuous Glucose Monitoring”, “Artificial Pancreas”, and “Machine Learning in Diabetes”. Inclusion criteria encompassed peer-reviewed original research articles, clinical trials, cohort studies, meta-analyses, and reviews that focused on pharmacological treatments, device-based interventions, or predictive analytics in type 2 diabetes [23,24]. Non-English publications, conference abstracts without complete data, and studies with inadequate methodological detail were excluded. Data extraction emphasized key variables such as patient demographics, intervention type, outcome measures (e.g., glycemic control, HbA1c reduction, complication prevention), and integration of predictive technologies, including feature selection techniques and machine learning models. The collected evidence was synthesized qualitatively to highlight emerging trends, existing gaps, and future opportunities in diabetes management. This rigorous methodological approach ensures the reliability, relevance, and reproducibility of the findings presented in this review [25,26]



### **ADVANCED PHARMACOLOGICAL TECHNIQUES:**

Recent advances in pharmacological management have significantly transformed the treatment landscape for type 2 diabetes mellitus by offering improved glycaemic control, reduced complication risks, and better patient adherence. Novel drug classes such as SGLT2 inhibitors promote glucose excretion through the kidneys and have demonstrated strong cardiovascular and renal protective effects, while GLP-1 receptor agonists enhance glucose-dependent insulin secretion, support weight loss, and reduce major adverse cardiovascular events [27]. Innovations in insulin therapy—including rapid-acting and ultra-long-acting analogues, inhaled insulin, and smart delivery devices—provide greater flexibility, more stable glucose regulation, and reduced hypoglycemia risk. Additionally, emerging nanotechnology-based delivery systems show promise for enhancing drug targeting, bioavailability, and therapeutic efficiency, potentially reducing the burden of frequent dosing. Together, these cutting-edge pharmacological approaches support a more personalised and comprehensive strategy for managing type 2 diabetes, addressing both metabolic control and associated comorbidities while paving the way for future advancements in diabetes care [28,29].

### **DEVICE-BASED AND NON-PHARMACOLOGICAL APPROACHES:**

Advancements in technology have significantly transformed the management of type 2 diabetes by complementing pharmacological therapies with precision monitoring, automated insulin delivery, and innovative biological approaches. Continuous glucose monitoring (CGM) systems offer real-time glucose data, reducing hypoglycemia, improving HbA1c, and enabling remote monitoring through cloud-based platforms. Insulin pumps provide programmable, physiological insulin delivery and, when paired with CGM in hybrid closed-loop systems, help maintain glucose within target ranges while minimising glycaemic variability. Artificial pancreas systems further advance diabetes care by automating insulin dosing through closed-loop mechanisms, yielding better glycaemic outcomes and improved quality of life [30,31].

Emerging therapies such as islet cell transplantation and gene-based interventions aim to restore endogenous insulin production, though challenges like donor limitations, immunosuppression, and safety concerns remain. Additionally, lifestyle interventions supported by digital health platforms, mobile apps, and wearable devices enhance patient engagement, promote behaviour change, and support continuous self-management. Together, these device-based and non-pharmacological strategies provide a comprehensive, patient-centred approach to diabetes care, improving treatment precision, reducing complications, and offering promising directions for future clinical practice.[32]





Figure 2 Flowchart of diabetes mellitus prediction system

### **MACHINE LEARNING AND PREDICTIVE ANALYTICS IN DIABETES MANAGEMENT:**

Machine learning (ML) and predictive analytics have become transformative tools in diabetes management, enabling earlier identification of high-risk individuals and guiding personalised intervention strategies. Unlike traditional statistical approaches, ML can analyse large, multidimensional datasets to detect subtle patterns associated with type 2 diabetes onset. Advanced algorithms such as Random Forest, Support Vector Machines, Neural Networks, Gradient Boosting, and deep learning models effectively identify key risk factors, including BMI, waist circumference, age, family history, lipid abnormalities, blood pressure, and lifestyle behaviours [33]. These models also generate highly accurate long-term predictive assessments, with some studies reporting over 90% accuracy for 5–8-year diabetes risk estimation. When integrated into Clinical Decision Support Systems (CDSS), ML enhances patient care by providing real-time alerts for hyperglycaemia risk, optimising treatment adjustments, and improving insulin dosing through the incorporation of continuous glucose monitoring (CGM) data. Despite these advances, challenges such as data privacy, algorithmic bias, dataset variability, and the need for rigorous clinical validation must be addressed to ensure safe and reliable implementation. Looking ahead, ML-driven diabetes management is expected to evolve toward precision medicine, combining genetic, metabolic, behavioural, and environmental data to create highly personalised intervention plans. Overall, the application of machine learning offers significant potential for early detection, risk stratification, and improved long-term outcomes in diabetes care [34].



### **CHALLENGES AND LIMITATIONS:**

Despite significant advancements in both pharmacological and technological interventions for diabetes mellitus, several challenges continue to impede optimal disease management. The economic burden remains a major concern, as cutting-edge therapies—including continuous glucose monitoring systems, insulin pumps, and newer drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors—are often costly and inaccessible to patients in low- and middle-income regions. Patient non-adherence to lifestyle modifications and medication regimens further limits therapeutic success, while technological literacy issues, especially among older adults, hinder effective use of mobile health applications and AI-driven tools. Additionally, the long-term safety and durability of emerging drugs and devices require further investigation to establish their efficacy over decades of use. Ethical issues and data privacy concerns associated with machine learning-based predictive models also pose barriers, as patient information must be protected while supporting clinical decision-making and research [35,36].

### **FUTURE PERSPECTIVES:**

The future of diabetes management is moving toward highly personalised and integrated care driven by rapid advancements in biomedical and digital technology. Precision medicine and pharmacogenomics are expected to tailor treatments to an individual's genetic and metabolic profile, improving therapeutic outcomes while minimising side effects. Artificial intelligence and big data analytics will further enhance disease prediction, optimise medication dosing, and support real-time clinical decision-making. As wearable technologies and closed-loop insulin delivery systems become more accessible, patients will benefit from reduced monitoring burdens and improved glycaemic control. Emerging non-invasive glucose monitoring methods also hold promise for improving comfort and adherence. On a broader scale, global health strategies must prioritise early screening, preventive care, and equitable access to innovative therapies. Strong collaboration among healthcare providers, pharmaceutical industries, and policymakers will be essential to effectively address the growing global impact of diabetes in the coming decades [37,38].

**CONCLUSION:**

Diabetes mellitus remains a major global health challenge, but recent advancements in pharmacological therapies, technological innovations, and predictive analytics have significantly reshaped its management. Modern drug classes such as SGLT2 inhibitors, GLP-1 receptor agonists, and next-generation insulin formulations offer improved glycaemic control alongside cardiovascular and renal protection. Complementary technologies—including continuous glucose monitoring, insulin pumps, closed-loop artificial pancreas systems, and digital health platforms—have enhanced precision, patient engagement, and overall quality of life. The integration of machine learning further empowers clinicians with accurate risk prediction and personalised treatment strategies, marking a major step toward proactive and data-driven diabetes care. Despite these advancements, challenges such as high treatment costs, limited accessibility, technological literacy barriers, and concerns regarding long-term safety and data privacy persist. Addressing these limitations through policy reform, equitable healthcare access, and ongoing research will be essential. Ultimately, the future of diabetes management lies in personalised, integrated, and technologically enabled care that not only improves disease outcomes but also reduces the global burden of diabetes in the years to come.

**REFERENCES:**

- 1) American Diabetes Association. (2023). Standards of medical care in diabetes—2023. *Diabetes Care*, 46(Suppl 1), S1–S154
- 2) Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England Journal of Medicine*, 373(22), 2117–2128.
- 3) Marso, S. P., Bain, S. C., Consoli, A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*, 375(19), 1834–1844.
- 4) Riddle, M. C., & Cefalu, W. T. (2021). Advances in insulin therapy: Rapid-acting and basal analogs. *Diabetes Technology & Therapeutics*, 23(4), 239–249.
- 5) Battelino, T., Danne, T., Bergenstal, R. M., et al. (2019). Clinical targets for continuous glucose monitoring data interpretation. *Diabetes Care*, 42(8), 1593–1603.
- 6) Sherr, J. L., & Tamborlane, W. V. (2020). Artificial pancreas systems for people with diabetes. *Nature Reviews Endocrinology*, 16(9), 525–535.
- 7) Rezende, L. F. M., et al. (2018). Lifestyle interventions in diabetes management: Evidence and perspectives. *Diabetology & Metabolic Syndrome*, 10(1), 48.
- 8) Rahman, M. M., et al. (2020). Machine learning in predicting diabetes complications: A systematic review. *Frontiers in Endocrinology*, 11, 241.
- 9) Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25(1), 44–56.
- 10) Nathan, D. M. (2015). Diabetes: Advances in diagnosis and treatment. *JAMA*, 314(10), 1052–1062.
- 11) Islam, M. T. et al. Diabetes mellitus prediction using different ensemble machine learning approaches. In 2020 11th International Conference on Computing, Communication and Networking Technologies (ICCCNT), pp. 1–7, IEEE, (2020).
- 12) World Health Organization 2020 Global report on diabetes, 2020. [Online]. Available: <https://apps.who.int/iris/handle/10665/204871>. (Accessed: May 2020).
- 13) Kumar, R. et al. Type 1 & Type 2. *World J. Pharm. Pharm. Sci.* 9(10), 838–850 (2020). Quichua, O. et al. Deep Learning Models for Predicting Epileptic Seizure Using iEEG Signals. *Electronics* 11(4). <https://doi.org/10.3390/electronics11040605> (2022).
- 14) Bin Tufail, A. et al. Early-Stage Alzheimer's Disease Categorization Using PET Neuroimaging Modality and Convolutional Neural Networks in the 2D and 3D Domains. *Sensors* 22, 12. <https://doi.org/10.3390/s22124609> (2022).
- 15) Raza, A. et al. A Hybrid Deep Learning-Based Approach for Brain Tumor Classification. *Electronics* 11(7). <https://doi.org/10.3390/electronics11071416> (2022).

- 16) Kaushik, H. et al. Diabetic Retinopathy diagnosis from Fundus images using stacked generalization of deep models. *IEEE Access* 9, 108276–108292. <https://doi.org/10.1109/ACCESS.2021.3101142> (2021).
- 17) Guefrechi, S. et al. Automated Diabetic Retinopathy Screening Using Deep Learning. *Multimed. Tools Appl.* 81. <https://doi.org/10.1007/s11042-024-18149-4> (2024).
- 18) Behera, D. K., Dash, S., Behera, A. K. & Dash, C. S. K. Extreme gradient boosting and soft voting ensemble classifier for diabetes prediction. In *2021 3rd IOTRS International Conference on Information Technology (ICIT)*, pp. 191–195, IEEE. (2021).
- 19) Wei, Y. et al. Exploring the causal relationships between type 2 diabetes and neurological disorders using a mendelian randomization strategy. *Medicine* 103(46), e40128. <https://doi.org/10.1097/MD.00000000000040128> (2024).
- 20) Li, Y. & Chen, W. A comparative performance assessment of ensemble learning for credit scoring. *Mathematics* 8(10), 1756 (2020).
- 21) Zhao, X., Zhang, Y. & Yan, Y. et al. Diabetes-related avoidable hospitalisations and its relationship with primary healthcare resourcing in China: a cross-sectional study from Sichuan Province. *Health Soc. Care Commun.*, 30(4), e1143–e1156. <https://doi.org/10.1111/hsc.13522> (2022).
- 22) Awotunde, J. B. et al. Explainable Machine Learning (XML) for Multimedia-Based Healthcare Systems: Opportunities, Challenges, Ethical and Future Prospects. In *Explainable Machine Learning for Multimedia Based Healthcare Applications*, pp. 21–46. (2023).  
Mujumdar, A. & Vaidehi, V. Diabetes prediction using machine learning algorithms. *Procedia Comput. Sci.* 165, 292–299 (2019).
- 23) Zhang, W., Zeng, F., Wu, X., Zhang, X. & Jiang, R. A comparative study of ensemble learning approaches in the classification of breast cancer metastasis. In *2009 International Joint Conference on Bioinformatics, Systems Biology and Intelligent Computing*, pp. 242–245, IEEE. (2009).
- 24) Kalaiselvi, C. & Nasira, G. M. A new approach for diagnosis of diabetes and prediction of cancer using ANFIS. In *2014 World Congress on Computing and Communication Technologies*, 188–190, IEEE. (2014).
- 25) Thongkam, J., Xu, G. & Zhang, Y. AdaBoost algorithm with random forests for predicting breast cancer survivability. In *2008 IEEE International Joint Conference on Neural Networks*, pp. 3062–3069, IEEE. (2008).
- 26) Lu, D.; Popuri, K.; Ding, G.W.; Balachandar, R.; Beg, M.F. Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images. *Sci. Rep.* 2018, 8, 5697. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)] [[Green Version](#)]
- 27) Liu, S.; Liu, S.; Cai, W.; Che, H.; Pujol, S.; Kikinis, R.; Feng, D.; Fulham, M.J. Multimodal neuroimaging feature learning for multiclass diagnosis of Alzheimer’s disease. *IEEE Trans. Biomed. Eng.* 2015, 62, 1132–1140. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)] [[Green Version](#)]
- 28) Liu, M.; Cheng, D.; Yan, W. Classification of Alzheimer’s Disease by Combination of Convolutional and Recurrent Neural Networks Using FDG-PET Images. *Front. Neuroinform.* 2018, 12, 35. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)] [[Green Version](#)]
- 29) Martí-Juan, G.; Sanroma-Guell, G.; Piella, G. A survey on machine and statistical learning for longitudinal analysis of neuroimaging data in Alzheimer’s disease. *Comput. Methods Programs. Biomed.* 2020, 189, 105348. [[Google Scholar](#)] [[CrossRef](#)] [[PubMed](#)]
- 30) Shahwar, T.; Zafar, J.; Almogren, A.; Zafar, H.; Rehman, A.U.; Shafiq, M.; Hamam, H. Automated Detection of Alzheimer’s via Hybrid Classical Quantum Neural Networks. *Electronics* 2022, 11, 721. [[Google Scholar](#)] [[CrossRef](#)]
- 31) Chételat, G.; Desgranges, B.; de la Sayette, V.; Viader, F.; Eustache, F.; Baron, J.C. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? *Neurology* 2003, 60, 1374–1377. [[Google Scholar](#)] [[CrossRef](#)]

- 32) Bouwman, F.H.; Schoonenboom, S.N.; van der Flier, W.M.; van Elk, E.J.; Kok, A.; Barkhof, F.; Blankenstein, M.A.; Scheltens, P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. *Neurobiol. Aging* 2007, 28, 1070–1074. [[Google Scholar](#)] [[CrossRef](#)]
- 33) Akbari, H.; Sadiq, M.T.; Rehman, A.U.; Ghazvini, M.; Naqvi, R.A.; Payan, M.; Bagheri, H.; Bagheri, H. Depression recognition based on the reconstruction of phase space of EEG signals and geometrical features. *Appl. Acoust.* 2021, 179, 108078. [[Google Scholar](#)] [[CrossRef](#)]
- 34) Rehman, A.U.; Jiang, A.; Rehman, A.; Paul, A.; Din, S.; Sadiq, M.T. Identification and role of opinion leaders in information diffusion for online discussion network. *J. Ambient. Intell. Humaniz. Comput.* 2020, 1–13. [[Google Scholar](#)] [[CrossRef](#)]
- 35) Ahmad, I.; Ullah, I.; Khan, W.U.; Rehman, A.U.; Adrees, M.S.; Saleem, M.Q.; Cheikhrouhou, O.; Hamam, H.; Shafiq, M. Efficient Algorithms for E-Healthcare to Solve Multiobject Fuse Detection Problem. *J. Healthc. Eng.* 2021, 2021, 9500304. [[Google Scholar](#)] [[CrossRef](#)]
- 36) American Diabetes Association (ADA). (2024). Standards of Medical Care in Diabetes—2024. *Diabetes Care*, 47(Suppl. 1), S1–S210.
- 37) Banting, F. G., & Best, C. H. (1922). “The Internal Secretion of the Pancreas.” *Journal of Laboratory and Clinical Medicine*, 7(3), 251–266.
- 38) Mering, J. von, & Minkowski, O. (1889). “Diabetes Mellitus nach Pankreasextirpation.” *Archiv für Experimentelle Pathologie und Pharmakologie*, 26, 371–387.

